focus -WSS

focus

author：fashion 2025-09-30 17:59:50 - browse：8

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： There's no autism epidemic. It's an autism diagnosis epidemic

WSS

With Roe v Wade overturned, abortion providers work to adapt

Lawsuit highlights wrinkle for disputes over surprise medical bills

The Karikó problem: Lessons for funding basic research

European officials brace for rough respiratory virus season

Primary care physicians play key roles in Alzheimer's management

The Readout: Lenmeldy, GLP

explore

focus

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

States should stop sabotaging methadone treatment reform

Affirmative action in medical school literally saved lives

Nobel honors Karikó and Weissman's enduring partnership

Medicare proposal to cover medical devices draws a mixed reaction

Abortion pill Supreme Court ruling could impact entire drug industry

Sports medicine is finally prioritizing gender equality

Stop Congress from blocking public access to science

Moonlake's readout produced a cash windfall. Risks remain

Setback for rare diseases as Taysha Gene Therapies pulls back

hotspot

Oprah kicked off a national conversation on obesity. Let's have it

New oral drug delivery patch is modeled after octopus tentacles

Abortion pill case raises question: who can sue the FDA?

Abortion pill Supreme Court ruling could impact entire drug industry

Washington mulls new rules to avert another Change Healthcare

Health insurers' Q3 question: how much care are people getting?

focus

knowledge

entertainment

knowledge